Cytotrait Secures £3 Million in Seed Funding
Cytotrait, a biotech company based in Manchester, has successfully raised £3 million in a seed funding round. The company specializes in developing technologies focused on plant organelle modification, which can significantly impact food and agricultural applications. This funding round was led by Northern Gritstone, with additional investments from the UK Innovation & Science Seed Fund and the Northern Universities Ventures Fund.
Advancing Plant Gene-Editing
Cytotrait is a spinout from The University of Manchester, primarily focused on creating advanced traits for crops. The company's proprietary technology, known as the Mutant Organelle Selection System (MOSS), allows precise gene editing within plant organelles like chloroplasts and mitochondria. This capability is crucial for achieving homoplasmy, a state where the desired genetic modification is consistently present across all organelles within a cell or plant.
By overcoming existing technical barriers in plant engineering, Cytotrait's platform supports both endogenous gene editing and the introduction of transgenes. This opens new possibilities for crop innovation, including improved resistance to diseases and enhanced nutritional content.
Leadership and Vision
Junwei Ji, Co-Founder and Executive Director of Cytotrait, is at the helm of the company's strategic direction. While specific quotes from Ji were not available, his leadership is central to advancing Cytotrait's mission of leveraging plant organelle technologies for agricultural improvements.
Specific Use of Funds
The funds raised in this seed round will primarily be used to further develop Cytotrait's gene-editing platform. This includes expanding their research capabilities and potentially hiring additional scientific personnel to accelerate product development. The investment will also support efforts to bring Cytotrait's innovations to market, enhancing the company's ability to offer solutions that meet the growing demand for sustainable agricultural practices.
Investor Confidence
The participation of prominent investors such as Northern Gritstone and the UK Innovation & Science Seed Fund underscores the confidence in Cytotrait's technology and its potential impact on the agricultural sector. The involvement of the Northern Universities Ventures Fund also highlights the academic roots and collaborative efforts behind the company's innovations.
Cytotrait's successful seed funding marks a significant step in advancing its mission to enhance crop traits through innovative gene-editing technologies. With the backing of key investors, the company is well-positioned to make meaningful strides in the field of agricultural biotechnology.